BRCA1 and breast carcinoma: The tendency for a significant proportion of gene carriers (particularly BRCA1) to have oestrogen-receptor-negative breast cancer suggests limited efficacy of SERMS in the treatment of breast cancer in this group (Lakhani et al, 2002).